John Anderson, MD: In Stockholm in September of 2015, there had been an announcement that, for the very first time, there was actually a cardiovascular benefit with one of the SGLT2 inhibitors. Remember, this came on top of 3 trials with DPP-4 inhibitors that had shown they met their primary endpoint for safety, but they did not show any cardiovascular benefit. And so, in Stockholm on a Thursday night, it was like a rock concert, with people trying to get in this room. No one knew the data except, of course, the investigators themselves. When they first got to the stage and presented the trial, they got to the results and showed a 13% reduction in 3-point MACE: that’s M-A-C-E, major adverse cardiovascular events. Everybody politely clapped. Good, they met their primary endpoint. The next thing they showed was the cumulative plot of cardiovascular death that showed a 38% reduction in cardiovascular death in the empagliflozin-treated group.
People were stunned. That’s an absolute risk reduction of 2.2%. In a cardiovascular outcomes trial, that is enormous. That was the first trial that let us know the SGLT2 inhibitor, empagliflozin, had really positive cardiovascular benefits. The other thing that was interesting was that these curves did not take a year to separate. These curves separated immediately and were statistically significant within 50 days of the onset of giving empagliflozin to that group. In addition, something that did not go into the empagliflozin label that has since come about from the FDA is a 35% reduction in admissions for heart failure. So, this was a game changer. This was a real game changer. And that’s why empagliflozin is the first drug in the United States that got the FDA approval for reduction of cardiovascular death in addition to an indication for type 2 diabetes for glycemic lowering.
This EMPA-REG trial was designed to try to not focus on glucose lowering. So, by the end of the trial, the difference in A1C was maybe 0.4%. The difference in systolic blood pressure was 3 or 4 mm Hg. Clearly, they were 2 points that did not drive this cardiovascular outcome. They combined both the 10- and the 25-mg dose of empagliflozin to get their results. The other interesting thing was that there was an actual reduction in progression to renal events, some 40%-plus reduction in renal events. That is why you’re now seeing a lot of chronic kidney disease and renal trials being done, which will probably, in the next couple of years, give us even more information about whether or not there’s renal protection in these medicines.
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More